The Effect of Montelukast Treatment on Elderly Patients Diagnosed with COVID-19

{ 'indexed': {'date-parts': [[2024, 8, 29]], 'date-time': '2024-08-29T00:25:36Z', 'timestamp': 1724891136393}, 'reference-count': 28, 'publisher': 'Selcuk University', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2024, 8, 5]]}, 'abstract': '<jats:p xml:lang="en">Abstract\r\n' '\r\n' 'Background/Aims:\r\n' '\r\n' 'The clinical course in COVID-19 patients can vary from asymptomatic cases to acute ' 'respiratory distress syndrome (ARDS), respiratory failure and multiorgan dysfunction. ' 'Clinical progression is thought to be mainly due to the release of proinflammatory cytokines. ' 'The most common symptoms are fever, cough, malaise, and shortness of breath. Montelukast, ' 'which is used in the treatment of seasonal allergic rhinitis and asthma, has brought its use ' 'in COVID-19 infection due to its anti-inflammatory and cytokine secretion-reducing effect. ' 'There are many studies in the literature that montelukast treatment has a positive effect on ' 'the prognosis and mortality of COVID-19. However, there are not enough studies evaluating the ' 'efficacy of montelukast treatment in elderly patients. The aim of our study is to evaluate ' 'the clinical and laboratory efficacy of montelukast treatment in patients aged 60 and over in ' 'COVID-19 disease, and to indicate the differences from the studies in the literature.\r\n' '\r\n' 'Methods\r\n' '\r\n' 'Our research was planned as a retrospective, single-center, observational study. The medical ' 'records of 75 COVID-19 patients aged 60 and over who were hospitalized in the internal ' 'medicine clinic of Ankara Bilkent City Hospital between September 2021 and December 2022 were ' 'included. Diagnosis of COVID-19 was confirmed with a reverse transcription polymerase chain ' 'reaction (RT-PCR) test from nasopharyngeal swab.\r\n' '\r\n' 'Results\r\n' '\r\n' 'Clinical findings and results were compared between the patients who received montelukast and ' 'the control group. There was no statistically significant difference between the two groups ' 'in terms of cough, dyspnea, gastroenteritis and oxygen theraphy requirement. There is no ' 'significant difference between the two groups in terms of the need for intensive care unit ' 'admission and mortality. The length of hospital stay was compared in both groups, it was ' '10.88±7.24 days in the control group and 10.51±5.44 days in the montelukast group, and there ' 'was no statistically significant difference between the groups. The laboratory parameters of ' 'the patients in both groups were compared. The neutrophil count and leukocyte count measured ' 'before hospitalization were found to be significantly lower in the patient group receiving ' 'montelukast (p=0.022, p=0.016). No significant difference was found in other laboratory ' 'parameters.\r\n' '\r\n' 'Conclusions\r\n' '\r\n' 'Although montelukast treatment has positive effects on prognosis in COVID-19 disease in the ' 'literature, a similar effect was not observed in the population aged 60 and over in our ' 'study. We did not find the positive effect of short-term montelukast treatment on the ' 'prognosis of patients aged 60 years and older who were hospitalized due to COVID-19. We ' 'thought that this was due to the low efficacy of montelukast in the elderly population. Our ' 'study is one of the first to examine montelukast therapy in the geriatric population with ' 'COVID-19.</jats:p>', 'DOI': '10.54005/geneltip.1352153', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 25]], 'date-time': '2024-08-25T19:01:17Z', 'timestamp': 1724612477000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Effect of Montelukast Treatment on Elderly Patients Diagnosed with COVID-19', 'prefix': '10.54005', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6575-4450', 'authenticated-orcid': True, 'given': 'Oğuzhan', 'family': 'Zengin', 'sequence': 'first', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0001-7379-8330', 'authenticated-orcid': True, 'given': 'Öztuğ', 'family': 'Aytekin', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0001-8396-4152', 'authenticated-orcid': True, 'given': 'Mustafa', 'family': 'Doğru', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6082-8323', 'authenticated-orcid': True, 'given': 'Burak', 'family': 'Göre', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0003-3539-8875', 'authenticated-orcid': True, 'given': 'Emine Sena', 'family': 'Sözen', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0001-7252-1292', 'authenticated-orcid': True, 'given': 'Merve', 'family': 'Evli', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0003-4552-0387', 'authenticated-orcid': True, 'given': 'Enes Seyda', 'family': 'Şahiner', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0002-8717-3013', 'authenticated-orcid': True, 'given': 'Osman', 'family': 'İnan', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}, { 'ORCID': 'http://orcid.org/0000-0003-2858-6229', 'authenticated-orcid': True, 'given': 'İhsan', 'family': 'Ateş', 'sequence': 'additional', 'affiliation': [ { 'name': 'SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ' 'ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ'}]}], 'member': '9978', 'published-online': {'date-parts': [[2024, 8, 5]]}, 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'crossref', 'unstructured': 'Khan, Ahsan R., et al. "Montelukast in hospitalized patients diagnosed ' 'with COVID-19." Journal of Asthma 59.4 (2022): 780-786.', 'DOI': '10.1080/02770903.2021.1881967'}, { 'key': 'ref2', 'doi-asserted-by': 'crossref', 'unstructured': 'Fidan, Cihan, and Ayşe Aydoğdu. "As a potential treatment of COVID-19: ' 'Montelukast." Medical hypotheses 142 (2020): 109828.', 'DOI': '10.1016/j.mehy.2020.109828'}, { 'key': 'ref3', 'doi-asserted-by': 'crossref', 'unstructured': 'Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, ' 'Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. ' 'Clinical, laboratory and imaging features of COVID-19: A systematic ' 'review and meta-analysis. Travel Med Infect Dis 2020:101623. PubMed ' 'PMID: 32179124. Epub 2020/03/18. eng.', 'DOI': '10.1016/j.tmaid.2020.101623'}, { 'key': 'ref4', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical ' 'characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, ' 'China. Allergy 2020. PubMed PMID: 32077115. Epub 2020/02/23. eng.', 'DOI': '10.1111/all.14238'}, { 'key': 'ref5', 'doi-asserted-by': 'crossref', 'unstructured': 'Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei ' 'C-L, Hui DSC, China Medical Treatment Expert Group for Covid-19, et al. ' 'Clinical characteristics of coronavirus disease 2019 in China. N Engl J ' 'Med. 2020;382(18):1708–1720. doi:10.1056/nejmoa2002032.', 'DOI': '10.1056/NEJMoa2002032'}, { 'key': 'ref6', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu ' 'H, et al. Clinical and immunological features of severe and moderate ' 'coronavirus disease 2019. J Clin Invest. 2020;130(5):2620– 2629. ' 'doi:10.1172/JCI137244.', 'DOI': '10.1172/JCI137244'}, { 'key': 'ref7', 'doi-asserted-by': 'crossref', 'unstructured': 'Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. ' '2020;130(5):2202–2205. doi:10.1172/ JCI137647.', 'DOI': '10.1172/JCI137647'}, { 'key': '#cr-split#-ref8.1', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen X, Zhang X, Pan J. Effect of Montelukast on Bronchopulmonary ' 'Dysplasia (BPD) and Related Mechanisms. Medical science monitor : int ' 'Med J Exp Clin Res 2019 Mar 13', 'DOI': '10.12659/MSM.912774'}, { 'key': '#cr-split#-ref8.2', 'unstructured': '25: 1886-93. PubMed PMID: 30862773. Pubmed Central PMCID: PMC6427930. ' 'Epub 2019/03/14. eng.'}, { 'key': 'ref9', 'doi-asserted-by': 'crossref', 'unstructured': 'Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini ' 'G, et al. COVID-19, cytokines and immunosuppression: what can we learn ' 'from severe acute respiratory syndrome? Clin Exp Rheumatol ' '2020;38(2):337–42. PubMed PMID: 32202240. Epub 2020/03/2eng.', 'DOI': '10.55563/clinexprheumatol/xcdary'}, { 'key': 'ref10', 'doi-asserted-by': 'crossref', 'unstructured': 'Erfen, Şebnem, and Esin Akbay Çetin. "Therapeutic and Preventive Effects ' 'of Piperine and its Combination with Curcumin as a Bioenhancer Against ' 'Aluminum-Induced Damage in the Astrocyte Cells." Neurotoxicity Research ' '(2022): 1-19.', 'DOI': '10.21203/rs.3.rs-1959715/v1'}, { 'key': 'ref11', 'unstructured': 'Mullol J, Callejas FB, Méndez-Arancibia E, Fuentes M, Alobid I, ' 'Martinez-Anton A, Valero A, Picado C, Roca-Ferrer J. Montelukast reduces ' 'eosinophilic inflammation by inhibiting both epithelial cell cytokine ' 'secretion (GM-CSF, IL-6, IL-8) and eosinophil survival.'}, { 'key': 'ref12', 'doi-asserted-by': 'crossref', 'unstructured': 'Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur ' 'Respir J. 2020;55(4):2000607. doi:10.1183/13993003.00607-2020.', 'DOI': '10.1183/13993003.00607-2020'}, { 'key': 'ref13', 'doi-asserted-by': 'crossref', 'unstructured': 'Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. ' 'Study of montelukast for the treatment of respiratory symptoms of ' 'post-respiratory syncytial virus bronchiolitis in children. Am J Respir ' 'Critical Care Med 2008;178(8):854–60. PubMed PMID: 18583576. Epub ' '2008/06/28. eng.', 'DOI': '10.1164/rccm.200706-910OC'}, { 'key': 'ref14', 'doi-asserted-by': 'crossref', 'unstructured': 'Noor A, Najmi MH, Bukhtiar S. Effect of Montelukast on ' 'bradykinin-induced contraction of isolated tracheal smooth muscle of ' 'guinea pig. Indian J Pharmacol 2011;43(4):445–9. PubMed PMID: 21845003. ' 'Pubmed Central PMCID: PMC3153711. Epub 2011/08/17. eng.', 'DOI': '10.4103/0253-7613.83119'}, { 'key': 'ref15', 'doi-asserted-by': 'crossref', 'unstructured': 'Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzie B, Santos-Dias A, ' 'Almeida-Oliveira AR, Aquino-Junior JCJ, Br ito AA, R igonato-Oliveira ' 'NC, Damaceno-Rodrigues NR, Oliveira APL, et al. Montelukast, ' 'leukotriene inhibitor, reduces LPS-induced acute lung inflammation and ' 'human neutrophil activation. Arch Bronconeumol. 2019;55(11):573–580. ' 'doi:10.1016/j.arbres.2019.05.003', 'DOI': '10.1016/j.arbres.2019.05.003'}, { 'key': 'ref16', 'unstructured': 'CBS New York. Though Not FDA Approved, Off-Label Singulair Showing ' 'Promise As Coronavirus Treatment, Say Doctors. 2020.'}, { 'key': 'ref17', 'doi-asserted-by': 'crossref', 'unstructured': 'Aigner, Ludwig, et al. "The leukotriene receptor antagonist montelukast ' 'as a potential COVID-19 therapeutic." Frontiers in molecular biosciences ' '7 (2020): 610132.', 'DOI': '10.3389/fmolb.2020.610132'}, { 'key': 'ref18', 'doi-asserted-by': 'crossref', 'unstructured': 'Kerget, Buğra, et al. "Effect of montelukast therapy on clinical course, ' 'pulmonary function, and mortality in patients with COVID‐19." Journal of ' 'Medical Virology 94.5 (2022): 1950-1958.', 'DOI': '10.1002/jmv.27552'}, { 'key': 'ref19', 'doi-asserted-by': 'crossref', 'unstructured': 'Sanghai, Nitesh, and Geoffrey K. Tranmer. "Taming the cytokine storm: ' 'repurposing montelukast for the attenuation and prophylaxis of severe ' 'COVID-19 symptoms." Drug discovery today 25.12 (2020): 2076-2079.', 'DOI': '10.1016/j.drudis.2020.09.013'}, { 'key': 'ref20', 'doi-asserted-by': 'crossref', 'unstructured': 'Columbo, Michele. "Asthma in the elderly: a double-blind, ' 'placebo-controlled study of the effect of montelukast." Asthma research ' 'and practice 3 (2017): 1-4.', 'DOI': '10.1186/s40733-017-0031-4'}, { 'key': 'ref21', 'doi-asserted-by': 'crossref', 'unstructured': 'Bozek, Andrzej, and Janne Winterstein. "Montelukast’s ability to fight ' 'COVID-19 infection." Journal of Asthma 58.10 (2021): 1348-1349.', 'DOI': '10.1080/02770903.2020.1786112'}, { 'key': 'ref22', 'doi-asserted-by': 'crossref', 'unstructured': 'Korenblat, Phillip E., et al. "Effect of age on response to zafirlukast ' 'in patients with asthma in the Accolate Clinical Experience and ' 'Pharmacoepidemiology Trial (ACCEPT)." Annals of Allergy, Asthma & ' 'Immunology 84.2 (2000): 217-225.', 'DOI': '10.1016/S1081-1206(10)62759-7'}, { 'key': 'ref23', 'doi-asserted-by': 'crossref', 'unstructured': 'Horiguchi T, Tachikawa S, Kondo R, et al. Comparative evaluation of the ' 'leukotriene receptor antagonist pranlukast versus the steroid inhalant ' 'fluticasone in the therapy of aged patients with mild bronchial asthma. ' 'Arzneimittelforschung. 2007;57(2):87–91.', 'DOI': '10.1055/s-0031-1296588'}, { 'key': 'ref24', 'doi-asserted-by': 'crossref', 'unstructured': 'Scicolone, Nicola, et al. "Safety and efficacy of montelukast as ' 'adjunctive therapy for treatment of asthma in elderly patients." ' 'Clinical Interventions in Aging (2013): 1329-1337.', 'DOI': '10.2147/CIA.S35977'}, { 'key': 'ref25', 'doi-asserted-by': 'crossref', 'unstructured': 'Bäck, Magnus. "Leukotriene signaling in atherosclerosis and ischemia." ' 'Cardiovascular drugs and therapy 23 (2009): 41-48.', 'DOI': '10.1007/s10557-008-6140-9'}, { 'key': 'ref26', 'doi-asserted-by': 'crossref', 'unstructured': 'Russmann S, Iselin HU, Meier D, et al. Acute hepatitis associated with ' 'montelukast. J Hepatol. 2003;38(5):694–695', 'DOI': '10.1016/S0168-8278(03)00085-0'}, { 'key': 'ref27', 'doi-asserted-by': 'crossref', 'unstructured': 'Sánchez G, Buitrago D. Effect of Montelukast 10 mg in Elderly Patients ' 'with Mild and Moderate Asthma Compared with Young Adults. Results of a ' 'Cohort Study. Open Respir Med J. 2018;12:67-74. Published 2018 Nov 14. ' 'doi:10.2174/1874306401812010067', 'DOI': '10.2174/1874306401812010067'}], 'container-title': 'Genel Tıp Dergisi', 'original-title': [], 'deposited': { 'date-parts': [[2024, 8, 28]], 'date-time': '2024-08-28T22:46:34Z', 'timestamp': 1724885194000}, 'score': 1, 'resource': {'primary': {'URL': 'http://dergipark.org.tr/en/doi/10.54005/geneltip.1352153'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 8, 5]]}, 'references-count': 28, 'URL': 'http://dx.doi.org/10.54005/geneltip.1352153', 'relation': {}, 'ISSN': ['2602-3741'], 'subject': [], 'published': {'date-parts': [[2024, 8, 5]]}}